The article discusses how poor enforcement record of the British Competition Markets Authority (CMA) leads to confusion and a difficult compliance environment in market. Topics discussed include CMA ongoing enforcement investigations, as of May 2016; CMA's chief executive Alex Chisholm's warning to pharmaceutical sector to expect substantial fines for breaches; and the CMA's caseload of basic breaches.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados